BioArctic in 15 seconds
BioArctic is an innovative Swedish biopharma company whose goal is to fundamentally change the treatment of serious neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and ALS. BioArctic has developed the world’s first disease-modifying treatment for Alzheimer’s disease, and several of the company’s other drug candidates build on the same principle: selective antibodies against misfolded proteins in the brain. In parallel, the company has developed BrainTransporter, which changes the way drugs are transported into the brain. With a globally approved drug and several new global agreements in place, BioArctic is now entering a new era of growth and increased focus on accelerating research that can improve the lives of even more people. The basis of BioArctic’s sustainability agenda is how the company’s innovations promote better health. The BioArctic share is traded on Nasdaq Stockholm’s Large Cap under the symbol BIOA B.
-
2003
BioArctic is founded
-
131
Employees
-
53
Markets for Leqembi
CEO statement
In 2025 BioArctic entered a new phase. Behind us we left that era which, over a period of just over 20 years, shaped the company we are today. 2025 was a fantastic year for BioArctic, with a breakthrough drug against Alzheimer’s disease in the global market, a broad and growing pipeline, several license agreement and a financial year that resulted in record-high profits. It is with pride that I look back on our first year in BioArctic’s new era of growth.
Gunilla Osswald, CEO BioArctic
BioArctic in numbers 2025
-
1999
Net revenue, SEK M
-
503
Royalties, SEK M
-
2190
Cash, cash equivalents and short term investments, SEK M
-
1259
Operating profit SEK M
-
≈ 11250
Potential future milestone license agreement (SEK M) Bristol Myers Squibb
-
≈ 6950
Potential future milestone license agreement (SEK M) Novartis
Vision
A world where science
defeats severe brain diseases.
Mission
BioArctic is an innovative biopharmaceutical company in precision neurology. Through world-leading research and collaborations, we create, develop and deliver innovative treatments for patients with severe brain diseases.
BioArctic’s antibodies
BioArctic has accrued unique expertise in developing antibodies against misfolded proteins in the central nervous system. This competence is now being used to continue driving progress forward, not only in Alzheimer’s disease, but also in other neurodegenerative diseases.
BrainTransporter – treatments against diseases of the brain
To further improve the outcome of treatments against diseases of the brain, BioArctic has developed its BrainTransporter technology. In preclinical trials, the method has been shown to yield up to 70 times the concentration of antibodies in the brain compared to antibodies unaided by a carrier protein – a result that, if it holds up in clinical trials, will open up new possibilities for treating diseases of the brain. This technology is being used in BioArctic’s own drug projects, and is also licensed externally through partnerships and collaborations.
Leqembi – approved in more than 50 countries
BioArctic has developed Leqembi, the world’s first fully approved disease-modifying treatment for Alzheimer’s disease. The drug has now been approved in more than 50 countries, and the development of new treatment forms and indications is continuing. The next paradigm shift in the treatment of Alzheimer’s disease is a subcutaneous autoinjector that patients can administer themselves at home, similar to today’s drugs for diabetes. Moreover, studies are ongoing in people with asymptomatic Alzheimer’s disease, i.e. people with elevated levels of amyloid-beta, but who are not yet showing any symptoms. The hope is that the disease can be treated before symptoms appear.
Sustainability – a natural part of BioArctic
BioArctic’s greatest opportunity to contribute to a sustainable future is through innovation and the development of safe and effective medicines against neurodegenerative diseases — areas with significant medical needs that affect the brain. Sustainability is deeply integrated into the organization’s daily activities to ensure a sustainable future for the patients and families we are helping, for our employees, and our shareholders.
BioArctic in the future
With groundbreaking research, a unique technology platform and a robust financial position, BioArctic has laid a foundation for continued value creation. These scientific successes are protected by an active patent strategy for both the antibody projects and the BrainTransporter platform. In parallel, BioArctic is putting intense effort into nurturing another major asset: the employees of an ever-growing organization.
BioArctic’s goal is that, in the long run, to become Sweden’s next great biopharma company
Goal
The goals for 2030 are to:
· Leqembi becomes an established treatment for Alzheimer’s disease
· The pipeline expands, with projects in all phases of development
· More successful global partnership are added
· The company is sustainable and profitable, with recurring dividends
The BioArctic share
The BioArctic share is traded on Nasdaq Stockholm’s Large Cap under the symbol BIOA B. The company’s market value increased 57 percent during the year and amounted to SEK 27.6 billion, while the number of shareholders in the company continued to increase. At year-end, BioArctic had 26,610 shareholders (23,833).
Historic share price performance
Share price trends and volume 2025
